Zosyn (piperacillin sodium/tazobactam sodium)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Piperacillin sodium and tazobactam sodium (piperacillin/tazobactam) is a fixed combination of the sodium salts of piperacillin (an extended-spectrum penicillin antibiotic) and tazobactam (a beta-lactamase inhibitor); tazobactam inactivates certain bacterial beta-lactamases and expands piperacillin's spectrum of activity against some bacteria that produce these beta-lactamases.
The fixed combination of piperacillin sodium and tazobactam sodium (piperacillin/tazobactam) is used for the treatment of moderate to severe infections caused by susceptible beta-lactamase-producing bacteria and certain other gram-negative or anaerobic bacteria. Piperacillin/tazobactam is used principally for the treatment of infections caused by susceptible gram-negative bacteria and for empiric treatment of polymicrobial infections such as mixed aerobic-anaerobic infections.
Generic name: piperacillin sodium/tazobactam sodium
Pronunciation: (PI-per-a-SIL-in/TAZ-oh-BAK-tam)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zosyn
Indications
The following indications are listed for Zosyn:
- Appendicitis
- Bacterial Pneumonia
- Bacteroides Appendicitis
- Bacteroides Complicated Appendicitis
- Bacteroides Peritonitis
- Complicated Skin And Skin Structure Infection
- Complicated Skin And Skin Structure Staphylococcus Aureus Infection
- Diabetic Foot Infection
- E. Coli Appendicitis
- E. Coli Complicated Appendicitis
- E. Coli Endometritis
- E. Coli Pelvic Inflammatory Disease
- E. Coli Peritonitis
- Haemophilus Influenzae Pneumonia
- Inflammatory Disease Of Female Pelvic Organs
- Intra-Abdominal Abscess
- Nosocomial Bacterial Pneumonia
- Peritonitis
- Skin And Skin Structure Infection
- Staphylococcus Aureus Skin And Skin Structure Infection
- Staphylococcus Nosocomial Pneumonia
Also known as: Abdominal Abscess, Appendicitis Due To Bacteroides Species, Appendicitis Due To E. Coli, Appendicitis Due To Escherichia Coli, Complicated Appendicitis Due To Bacteroides Species, Complicated Appendicitis Due To E. Coli, Complicated Appendicitis Due To Escherichia Coli, Complicated Bacterial Skin And Skin Structure Infection, Complicated Skin And Skin Soft Tissue Infection, Complicated Skin And Skin Structure Bacterial Infection, Complicated Staphylococcus Aureus Skin And Skin Soft Tissue Infection, Endometritis Due To E. Coli, Endometritis Due To Escherichia Coli, H. Flu Pneumonia, H. Influenzae Pneumonia, Hemophilus Influenzae Pneumonia, Hospital-Acquired Bacterial Pneumonia, Infection Of Skin And/Or Subcutaneous Tissue, Influenza Bacillus Pneumonia, Nosocomial Pneumonia Due To Staphylococcus Species, Pelvic Inflammatory Disease Due To E. Coli, Pelvic Inflammatory Disease Due To Escherichia Coli, Peritonitis Due To Bacteroides, Peritonitis Due To Escherichia Coli, Pfeiffer's Bacillus Pneumonia, Pid Due To Escherichia Coli, Pneumonia Due To Haemophilus Influenzae, Skin And Skin Soft Tissue Staphylococcus Aureus Infection, Skin And Soft Tissue Skin Infection.
Dosing
Piperacillin/tazobactam is a fixed combination of piperacillin sodium and tazobactam sodium; potency of each component is expressed in terms of the base. The commercially available fixed combination contains an 8:1 ratio of piperacillin to tazobactam.
Dosage of piperacillin/tazobactam usually is expressed as the total (sum) of the dosage of each of the 2 components (i.e., dosage of piperacillin plus dosage of tazobactam). However, dosage of piperacillin/tazobactam for pediatric patients often is expressed in terms of the piperacillin component.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Available human data regarding use of piperacillin/tazobactam during pregnancy are inadequate to inform a drug-associated risk for major birth defects and miscarriage. Piperacillin and tazobactam both cross the human placenta.
Reproduction studies in pregnant mice and rats using IV piperacillin/tazobactam (up to 1-2 times the human dosage of piperacillin and 2-3 times the human dosage of tazobactam based on body surface area) did not reveal evidence of teratogenicity or fetal structural abnormalities; however, intraperitoneal administration in rats at doses less than the maximum recommended human daily dosage based on body surface area given prior to mating and throughout gestation or from gestation day 17 through lactation day 21 resulted in maternal toxicity, reduced litter size, and effects on peri- and postnatal development (e.g., reduced pup weights, increased stillbirths, increased pup mortality, ossification delays, rib variations).
Piperacillin is distributed into human milk; it is not known whether tazobactam is distributed into human milk. Effects of the drugs on breast-fed infants or milk production are not known.
The developmental and health benefits of breast-feeding should be considered along with the woman's clinical need for piperacillin/tazobactam and potential adverse effects on the breast-fed infant from the drug or from the underlying maternal condition.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.